We claim:

1. A modified *Staphylococcus aureus* Cas9 polypeptide comprising the amino acid sequence of SEQ ID NO: 14.

2. A chimeric nuclease comprising a modified I-Tevl nuclease domain, a linker, an RNA-guided nuclease *Staphylococcus aureus* Cas9 domain comprising a D10E mutation and a guide RNA.

3. A pharmaceutically-acceptable formulation comprising the chimeric nuclease according to claim 2, a guide RNA, a lipid nanoparticle and a pharmaceutically acceptable carrier thereof.

4. The formulation according to claim 3, wherein said lipid nanoparticle further comprises exogenous donor DNA.

5. The chimeric nuclease of claim 2 for use in a method to edit genomic DNA of a cell or organism.

6. The formulation according to claim 3 or 4, wherein said formulation further comprises an excipient.

7. The formulation according to claim 6, wherein said excipient is selected from the group consisting of excipients polysorbates, polyphosphates, calcium chlorides, sodium chloride, sodium citrates, sodium hydroxide, sodium phosphates, sodium ethylenediaminetetraacetic acid, potassium chloride, potassium phosphate and starches, or mixtures of these substances.

8. Use of the formulation of claim 3 or 4 in the manufacture of a medicament for a method of treating a lung-related disease in a patient in need thereof.

9. The use according to claim 8, wherein said disease is cystic fibrosis.

10. The use according to claim 8, wherein said chimeric nuclease targets and cleaves the *CFTR* gene.

11. The use according to claim 10, wherein the *CFTR delta F508* mutation is cleaved from the *CFTR* gene.

12. The use according to claim 8, wherein said disease is cancer.

13. The use according to claim 12, wherein said chimeric nuclease targets and cleaves the *EGFR* gene.

14. The use according to claim 12, wherein said cancer is non-small cell lung cancer.

15. The chimeric nuclease according to claim 2, wherein said linker is selected from the group consisting of SEQ ID NOS: 7 – 12.

16. The chimeric nuclease according to claim 2, wherein the modified RNA-guided nuclease *Staphylococcus aureus* Cas9 is the polypeptide according to claim 1.

17. The chimeric nuclease according to claim 2, comprising a guide RNA comprising the RNA sequence of SEQ ID NO: 15.

18. The chimeric nuclease according to claim 2, comprising a guide RNA comprising the RNA sequence of SEQ ID NO: 21.

19. The chimeric nuclease according to claim 2, comprising a guide RNA comprising the entire RNA sequence of SEQ ID NO: 16.

20. The chimeric nuclease according to claim 2, wherein said linker comprises one or more of the group consisting of SEQ ID NOS: 9 – 12.

21. The chimeric nuclease according to claim 2, wherein said nuclease *Staphylococcus aureus* Cas9 contains an Ala^{580} or Ala^{557} mutation.

22. The chimeric nuclease of claim 2, wherein the *Staphylococcus aureus* Cas9 domain comprises SEQ ID NO: 14.

23. The chimeric nuclease of claim 2, wherein the I-Tevl nuclease domain comprises SEQ ID NO: 6 or a fragment thereof.

24. The polypeptide of claim 1, wherein the modified *Staphylococcus aureus* Cas9 further comprises a H557A mutation.